在高血压患者和阻塞性睡眠呼吸暂停患者中,通过使用一种新的诊断算法,增强了对原发性阿尔多斯特主义的检测
Shruti N Shah1, Kyla Wright1,2, Insoo Suh3
1NYU Grossman School of Medicine, New York, NY, USA.
Endocrine
|June 17, 2025
概括
与目前的指导方针相比,Vaidya和Carey算法显著增加了阻塞性睡眠呼吸暂停和高血压患者的初级阿尔多斯特主义 (PA) 检测. 对于这种诊断不足的疾病,需要更强大的查.
科学领域:
- 内分泌学 在内分泌学.
- 心脏病学 心脏病学
- 睡眠医学 睡眠医学
背景情况:
- 原发性阿尔多斯特隆症 (PA) 是经常被诊断不足的二次高血压的原因,与相当大的心血管疾病相关.
- 阻塞性睡眠呼吸暂停 (OSA) 和高血压 (HTN) 是常见的并发症,PA查在这个人群中可能是有益的.
- 目前的查指南可能无法充分识别所有PA病例.
研究的目的:
- 评估伴并发性阻塞性睡眠呼吸暂停 (OSA) 和高血压 (HTN) 的成年人中原发性阿尔多斯特隆症 (PA) 查率.
- 为了比较2016年内分泌学会指南的诊断产量与PA查的Vaidya & Carey算法.
主要方法:
- 分析了457名患有OSA和HTN的成年人的队列.
- 在97名患者中进行了PA查,使用血清阿尔多素,阿尔多素与血胆固醇活性比率 (ARR) 和血胆固醇活性 (PRA).
- 查结果与内分泌学会指南 (血清阿尔多和ARR) 和Vaidya&Carey算法 (血清阿尔多和PRA) 进行了比较.
主要成果:
- 与内分泌学会指南 (7%) 相比,Vaidya和Carey算法发现了明显更高的PA阳性率 (33%).
- 根据内分泌学会的标准,很大一部分患者 (26%) 最初是负面的,使用Vaidya & Carey算法被重新归类为阳性.
- 韦德亚和凯里算法还澄清了11个以前不确定的病例,将它们归类为由于缺少氨酸抑制而导致的负面.
结论:
- 韦德亚和凯里算法证明了在患有OSA和HTN的患者中改善初级阿尔多斯特主义检测的潜力.
- 这种算法可能有助于澄清不确定的情况,并识别以前未被识别的PA.
- 鉴于与未经治疗的PA相关的显著发病率,更全面的查策略是合理的.
相关概念视频
Sleep Apnea
227
Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
The condition is more prevalent among...
227
Hypertension III: Clinical Manifestations and Diagnostic Studies
60
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
60
Heart Failure VI: Adjunct Therapies
39
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
39
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
526
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
526
Antihypertensive Drugs: Direct Renin Inhibitors
849
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
849
Hypertension I: Introduction
89
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
89


